Abstract: The present disclosure relates to stable formulations comprising amino acid sequences and polypeptides binding to cytotoxic T-lymphocyte associated antigen 4 (CTLA4). In another aspect, the present disclosure relates, in part, to formulations comprising improved heavy-chain immunoglobulin single variable domains (also referred to herein as “ISVs” or “ISVDs”, or “multivalent VHH single domain antibodies”) binding to CTLA4, as well as to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise such ISVDs. Also provided are methods of treating various cancers and chronic infections with the formulations of the disclosure.

Abstract: In certain aspects, the present disclosure provides stable, liquid pharmaceutical formulations comprising a recombinant fusion protein comprising an extracellular domain (ECD) of human activin receptor type-IIA (ActRIIA) protein or variant thereof linked to a constant domain of an immunoglobulin, such as human IgG1 Fc domain and one or more pharmaceutical additives and/or excipients.

Abstract: Ground-accessing elevator systems and methods are provided for transporting personnel between the ground level and one or more decks of multi-level vehicle such as a fixed-wing aircraft. The vehicle elevator systems and methods may be implemented using a multi-track guide rail system configured to guide an elevator car between the ground and two or more levels within a vehicle. The multi-track guide rail system may include an intra-vehicle track fixed to the vehicle structure and configured to guide the elevator car between decks of the vehicle, and a separate deployment track may be configured to telescope downward from the intra-vehicle guide rail track to guide the elevator car during deployment to the ground from the vehicle.

Abstract: The present invention provides a compound of Formula I (The formula should be inserted here) as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

Abstract: Ground-accessing elevator systems and methods are provided for transporting personnel between the ground level and one or more decks of multi-level vehicle such as a fixed-wing aircraft. The vehicle elevator systems and methods may be implemented using a multi-track guide rail system configured to guide an elevator car between the ground and two or more levels within a vehicle. The multi-track guide rail system may include an intra-vehicle track fixed to the vehicle structure and configured to guide the elevator car between decks of the vehicle, and a separate deployment track may be configured to telescope downward from the intra-vehicle guide rail track to guide the elevator car during deployment to the ground from the vehicle.

Abstract: The present invention provides a compound of Formula I (The formula should be inserted here) as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

Abstract: Ground-accessing elevator systems and methods are provided for transporting personnel between the ground level and one or more decks of multi-level vehicle such as a fixed-wing aircraft. The vehicle elevator systems and methods may be implemented using a multi-track guide rail system configured to guide an elevator car between the ground and two or more levels within a vehicle. The multi-track guide rail system may include an intra-vehicle track fixed to the vehicle structure and configured to guide the elevator car between decks of the vehicle, and a separate deployment track may be configured to telescope downward from the intra-vehicle guide rail track to guide the elevator car during deployment to the ground from the vehicle.

Abstract: Ground-accessing elevator systems and methods are provided for transporting personnel between the ground level and one or more decks of multi-level vehicle such as a fixed-wing aircraft. The vehicle elevator systems and methods may be implemented using a multi-track guide rail system configured to guide an elevator car between the ground and two or more levels within a vehicle. The multi-track guide rail system may include an intra-vehicle track fixed to the vehicle structure and configured to guide the elevator car between decks of the vehicle, and a separate deployment track may be configured to telescope downward from the intra-vehicle guide rail track to guide the elevator car during deployment to the ground from the vehicle.

Abstract: In its many embodiments, the present invention discloses novel compounds, as inhibitors of HDM2 protein methods for preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of treatment, prevention, inhibition, of one or more diseases associated with the HDM2 protein or P53 using such compounds or pharmaceutical compositions.

Abstract: Methods and systems for processing signals to minimize the effects of dye crosstalk. Deconvolution of multiplexed dye signals can include corrections for residual error determined from experimental measurements. Residual error corrections can account for reaction or assay specific factors and modify the subsequent filtering of signals. Correction values can be determined for specific dye-probe conjugates to minimize dye crosstalk and may be combined with residual error correction to further minimize errors in spectral deconvolution. Apparatus, systems, and computer-readable media can process signals and modify filters based on values obtained using the methods.

Abstract: Disclosed is a compound of the formula: and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating protein kinase mediated diseases using the compound of formula 1.0. Also disclosed are methods of treating cancer using a compound of formula 1.0. The disclosed methods also include combination therapies wherein the compound of formula 1.0 is administered in combination with at least one addition pharmaceutically active ingredient.

Abstract: A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, are useful in treating diseases, disorders, or conditions such as immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease.